Raymond James Financial, Inc. vs Roivant Sciences Ltd. Common Shares — how do they compare? Raymond James Financial, Inc. trades at $159.3 (market cap $30.51B), while Roivant Sciences Ltd. Common Shares trades at $35.08 (market cap $24.72B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 74 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| RJF | ROIV | |
|---|---|---|
Market Cap | $30.51B | $24.72B |
Volume | 1,206,253 | 6,279,442 |
Sector | Financials | Health |
52-Week High | $181.18 | $41.81 |
52-Week Low | $140.89 | $16.04 |
Typical Hold Time | 74 Days | 1 Days |
Enterprise Value | $24.37B | $20.99B |
Dividend Yield | 1.36% | — |
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $159.04, up 1.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 estimate. Revenue has grown steadily from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. A quarterly dividend of $0.54 was declared, payable in October 2026.
The outlook is supported by solid fundamentals, including a P/E of 13.83 and ROE of 18.48%, but risks include volatile cash flows from investing activities and rising expenses. Analysts are neutral with a consensus price target of $184.00, implying potential upside. Investor sentiment is mixed amid recent institutional buying and selling activity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →